Wells Fargo Believes Amphastar Pharmaceuticals (NASDAQ: AMPH) Won’t Stop Here

By Carrie Williams

In a report released today, David Maris from Wells Fargo maintained a Buy rating on Amphastar Pharmaceuticals (AMPHResearch Report). The company’s shares closed yesterday at $20.71, close to its 52-week high of $20.99.

According to TipRanks.com, Maris is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -10.8% and a 33.1% success rate. Maris covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Kala Pharmaceuticals Inc, and Emergent Biosolutions.

Amphastar Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $22.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.99 and a one-year low of $14.40. Currently, Amphastar Pharmaceuticals has an average volume of 157.1K.

Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2018, Richard Prins, a Director at AMPH sold 10,000 shares for a total of $178,100.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments.